No benefit for adjuvant ibandronate at 3 years in early breast cancer

Share :
Published: 13 Dec 2016
Views: 1860
Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands

Prof Linn speaks with ecancertv at SABCS 2016 to discuss the impact of adjuvant bisphosphonate therapy on patients with early stage breast cancer, finding that there was no significant improvement through its addition after 3 years follow up.

Weighing the slight trends of gastrointestinal side effects against lowered risk of bone metastases, Prof Linn considers if 3 years is an adequate follow up to see the full effects of added bisphosphonate therapy, and notes patient concerns over osteonecrosis of the jaw as a side effect of treatment.

These results were first presented in a press conference session, with video coverage available here.